Stifel Nicolaus Lowers Thermo Fisher Scientific (NYSE:TMO) Price Target to $665.00

Thermo Fisher Scientific (NYSE:TMO) had its target price cut by Stifel Nicolaus from $680.00 to $665.00 in a research report report published on Thursday morning, Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Other analysts have also issued reports about the stock. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They issued a “buy” rating and a $680.00 price objective on the stock. Evercore ISI decreased their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday. Bank of America boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Finally, Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Trading Down 0.5 %

Shares of NYSE TMO opened at $554.38 on Thursday. The stock has a market capitalization of $211.62 billion, a P/E ratio of 35.56, a PEG ratio of 3.75 and a beta of 0.77. Thermo Fisher Scientific has a 1-year low of $420.21 and a 1-year high of $627.88. The business’s 50 day moving average is $605.12 and its two-hundred day moving average is $584.07. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.69 EPS. As a group, research analysts expect that Thermo Fisher Scientific will post 21.72 EPS for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Brookstone Capital Management increased its stake in Thermo Fisher Scientific by 252.4% during the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after purchasing an additional 3,142 shares in the last quarter. New England Research & Management Inc. acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth about $349,000. KRS Capital Management LLC grew its stake in Thermo Fisher Scientific by 6.2% during the 1st quarter. KRS Capital Management LLC now owns 1,430 shares of the medical research company’s stock valued at $831,000 after purchasing an additional 83 shares during the last quarter. S.E.E.D. Planning Group LLC raised its stake in shares of Thermo Fisher Scientific by 3.8% in the first quarter. S.E.E.D. Planning Group LLC now owns 10,178 shares of the medical research company’s stock worth $5,916,000 after purchasing an additional 371 shares during the last quarter. Finally, Independence Bank of Kentucky lifted its holdings in shares of Thermo Fisher Scientific by 4.3% during the first quarter. Independence Bank of Kentucky now owns 2,715 shares of the medical research company’s stock worth $1,578,000 after purchasing an additional 112 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.